https://www.selleckchem.com/pr....oducts/polyinosinic-
Anti-IL-17A IgG/κ monoclonal antibody CJM112 binds both IL-17A and IL-17AF. The purpose of this First-in-Human study was to assess CJM112 effects on safety and efficacy in patients with moderate to severe plaque psoriasis. This study had two parts single ascending doses of 5-450mg subcutaneous (s.c.) CJM112 (SAD) and multi-dose parallel groups of CJM112 15mg, 50mg and 150mgs.c. low frequency or high frequency (MD). SAD/MD were double-blind, randomized and placebo-controlled; MD also included a secukinumab 15
Like
Comment
Share
